{"id":242243,"date":"2026-09-11T08:51:18","date_gmt":"2026-09-11T03:21:18","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=242243"},"modified":"2026-09-11T08:51:18","modified_gmt":"2026-09-11T03:21:18","slug":"mnc-pharma-stock-rises-87-percent-in-3-years","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/mnc-pharma-stock-rises-87-percent-in-3-years\/","title":{"rendered":"This MNC Pharma Stock Rises 87% in 3 Years: What Powered the Rally?"},"content":{"rendered":"

CMP approximately Rs 2,841 (10 Sep 2026). 3-year return 87.41%. 52W range Rs 2,088 to Rs 3,121. Market cap around Rs 48,125 Cr. FY26 PAT Rs 1,036 Cr vs Rs 611 Cr in FY23.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

GlaxoSmithKline Pharmaceuticals, the Indian arm of GSK plc, is the MNC pharma stock behind a 3-year return of approximately 87%. Net profit rose from about Rs 611 crore in FY23 to Rs 1,036 crore in FY26 as margins widened and oncology and vaccine launches added growth. The share now trades near Rs 2,841 at a PE of about 46, close to the latest brokerage target.<\/p>\n<\/div>\n

This MNC pharma stock has turned Rs 1 lakh into roughly Rs 1.87 lakh over the past three years, without taking on debt or diluting shareholders. The share delivered a 3-year return of 87.41% as of 10 September 2026, ranking 49th in a screen of 101 large-cap and mid-cap NSE shares.<\/p>\n

The company is GlaxoSmithKline Pharmaceuticals Ltd<\/a> (NSE: GLAXO)<\/strong>, the Indian listed arm of the British drugmaker GSK plc, which owns 75% of it. The GSK Pharma share closed at approximately Rs 2,841 on 10 September 2026, down about 1.57% for the day, giving the company a market value of around Rs 48,100 crore. It sells household antibiotic brands such as Augmentin and Ceftum, respiratory drugs like Nucala and Trelegy, and vaccines including Shingrix.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n